New Lipoglycopeptides

  title={New Lipoglycopeptides},
  author={Dr George G. Zhanel and Divna Calic and Frank Schweizer and Sheryl Zelenitsky and Heather Adam and Philippe R. S. Lagac{\'e}-Wiens and Ethan Rubinstein and Alfred S. Gin and Daryl J. Hoban and James A Karlowsky},
Dalbavancin, oritavancin and telavancin are semisynthetic lipoglycopeptides that demonstrate promise for the treatment of patients with infections caused by multi-drug-resistant Gram-positive pathogens. Each of these agents contains a heptapeptide core, common to all glycopeptides, which enables them to inhibit transglycosylation and transpeptidation (cell… CONTINUE READING